ArticleOncoTargets and therapy2019

Ceritinib for an anaplastic lymphoma kinase rearrangement-positive patient previously treated with alectinib with poor performance status.

Rui Kitadai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.